Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 5, 2010, Pages 331-335

  Salie, Rishard ^a   Silver, Richard ^b  

^a SAN GmbH   (Switzerland)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Birth defects; Congestive heart failure; Hepatic toxicity; Hypophosphatemia; Periorbital edema

Indexed keywords

ALFENTANIL; ANTACID AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLARITHROMYCIN; DEXAMETHASONE; DIURETIC AGENT; IMATINIB; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STEROID; TELITHROMYCIN; UNINDEXED DRUG; VORICONAZOLE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ANASARCA; ANEMIA; ARTHRALGIA; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIRTH DEFECT; BLEEDING; BODY WEIGHT; BRAIN EDEMA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EDEMA; EXFOLIATIVE DERMATITIS; FATIGUE; FLUID RETENTION; FOOD DRUG INTERACTION; GENERALIZED EXANTHEMATOUS PUSTULOSIS; GRAPEFRUIT JUICE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYGROMA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JOINT EFFUSION; KIDNEY FAILURE; LEUKEMIA RELAPSE; LIFESPAN; LIVER DYSFUNCTION; LIVER TOXICITY; MACULOPAPULAR RASH; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAPILLEDEMA; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PHOSPHATURIA; PHOTOSENSITIVITY DISORDER; PHYSICIAN; PLEURA EFFUSION; PREGNANCY; PREGNANCY OUTCOME; PROGNOSIS; PRURITUS; PUSTULOSIS; RASH; RETINA EDEMA; RETINA MACULA EDEMA; REVIEW; SCOLIOSIS; SIDE EFFECT; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; UMBILICAL HERNIA; VOMITING; DRUG ANTAGONISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 79952279792     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.065     Document Type: Article

References (58)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25:85-109.
2. Druker BJ, O'Brien SG, Cortes J, et al. Chronic myelogenous leukemia. Blood (Am Soc Hematol Educ Program) 2002:111-35.
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-53. (Pubitemid 40446252)
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17. (Pubitemid 44903745)
5. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109:58-60. (Pubitemid 46053043)
6. Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leuk Res 2009; 33:1079-81.
7. O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008; 112:76 (abstract 186).
8. Kantarjian HM, Sawyers C, Hochhaus A, et al. Six-year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-A (IFN) refractoriness/intolerance. Blood 2006; 108:130a (abstract 428).
9. Tong W, Kantarjian H, O'Brien S, et al. Imatinib frontline therapy is safe and effective in patients with chronic myeloid leukemia (CML) with liver and/or renal dysfunction. Blood 2008; 112:741 (abst ract 2126).
10. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505-8.
11. Centers for Disease Control and Prevention [Web site]. Birth defects. Available at: http://www.cdc.gov/ncbddd/bd. Accessed: September 15, 2010.
12. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908-16. (Pubitemid 44175142)
13. Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol 2006; 58:567-73.
14. Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233-7. (Pubitemid 47281421)
15. Ribeiro AL, Marcolino MS, Bittencourt HN, et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 2008; 32:1809-14.
16. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43:974-8. (Pubitemid 46505099)
17. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106:3068-72. (Pubitemid 35440290)
18. Barton JC, Jones SC, Lamberth WC, et al. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 2002; 71:139-40.
19. Ebnoether M, Stentoft J, Ford J, et al. Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002; 359:1751-2. (Pubitemid 34607093)
20. Bruck P, Wassmann B, Lopez ER, et al. Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. Leuk Res 2004; 28:1153-7. (Pubitemid 39243238)
21. Ramar K, Potti A, Mehdi SA. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. J Clin Oncol 2003; 21:172-3.
22. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95:881-7. (Pubitemid 34839681)
23. Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (Lond) 2004; 18:760-2. (Pubitemid 39117443)
24. Goldsby R, Pulsipher M, Adams R, et al. Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol 2002; 24:694-5. (Pubitemid 35285115)
25. Breccia M, D'Elia GM, D'Andrea M, et al. Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib. Eur J Haematol 2005; 74:89-90. (Pubitemid 40143696)
26. Moore JC, Dennehey CF, Anavim A, et al. Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia. Eur J Haematol 2006; 76:444-6.
27. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003; 19:371-5. (Pubitemid 37013010)
28. Kusumi E, Arakawa A, Kami M, et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004; 18:1138-9. (Pubitemid 38786973)
29. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol 2008; 52:331-3.
30. Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002; 17:685-7. (Pubitemid 34308834)
31. Foringer JR, Verani RR, Tjia VM, et al. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005; 39:2136-8. (Pubitemid 41745965)
32. Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44:1239-41. (Pubitemid 36609120)
33. Francois H, Coppo P, Hayman JP, et al. Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 2008; 51:298-301.
34. Tournis S, Lyritis GP. Imatinib and altered bone and mineral metabolism [erratum published in: N Engl J Med 2006; 355:1627]. N Engl J Med 2006; 355:627; author reply 8-9. (Pubitemid 44200665)
35. Grey A, O'Sullivan S, Reid IR, et al. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006; 355:2494-5. (Pubitemid 44903777)
36. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006-13.
37. Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111:2538-47.
38. Breccia M, Carmosino I, Russo E, et al. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005; 74:121-3. (Pubitemid 40175315)
39. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006; 5:228-31.
40. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48:201-6. (Pubitemid 36232317)
41. Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117:620-2.
42. Dogra S, Kanwar AJ. Imatinib mesylate-induced maculopapular drug rash. Natl Med J India 2003; 16:285-6. (Pubitemid 37493265)
43. Banka N, Aljurf M, Hamadah I. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. Dermatology 2003; 207:329-30. (Pubitemid 37329210)
44. Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother 2003; 37:1818-20. (Pubitemid 37466580)
45. Schwarz M, Kreuzer KA, Baskaynak G, et al. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69:254-6. (Pubitemid 35448131)
46. Pavithran K, Thomas M. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 2005; 71:288-9. (Pubitemid 41191373)
47. Vidal D, Puig L, Sureda A, et al. Sti571-induced Stevens-Johnson Syndrome. Br J Haematol 2002; 119:274-5.
48. Clark SH, Duvic M, Prieto VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol 2003; 30:279-81. (Pubitemid 36555138)
49. Oka S, Yokote T, Hara S, et al. Effective treatment of a case of refractory mycosis fungoides with imatinib. Br J Haematol 2006; 133:353.
50. Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98:2483-7. (Pubitemid 37466664)
51. Prabhash K, Doval DC. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol 2005; 71:287-8.
52. Pasmatzi E, Monastirli A, Matsouka P, et al. Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate. Acta Derm Venereol 2003; 83:391-2. (Pubitemid 37281557)
53. Breccia M, Latagliata R, Carmosino I, et al. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. Leukemia 2004; 18:182. (Pubitemid 38159461)
54. Ho AY, Deacon A, Osborne G, et al. Precipitation of porphyria cutanea tarda by imatinib mesylate? Br J Haematol 2003; 121:375. (Pubitemid 36560607)
55. Liu D, Seiter K, Mathews T, et al. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res 2004; 28(suppl 1):S61-3. (Pubitemid 38251500)
56. Dib EG, Ifthikharuddin JJ, Scott GA, et al. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk Res 2005; 29:233-4. (Pubitemid 39647519)
57. Baskaynak G, Kreuzer KA, Schwarz M, et al. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003; 70:231-4. (Pubitemid 36511317)
58. Bekkenk MW, Vermeer MH, Meijer CJ, et al. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 2003; 102:4243. (Pubitemid 37487014)